News

Cemiplimab demonstrated a 68% reduction in recurrence risk for high-risk CSCC in the phase 3 C-POST trial, according to Regeneron’s latest findings.

Balancing ethics, aesthetics, and patient expectations is crucial in dermatology to ensure safe, responsible, and ethical care.

A case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, highlighting unique histopathology and complications.

Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.

Shanna Miranti, MPAS, PA-C, discusses the Umary hyaluronic acid tablets that were recalled in fall 2024.

The new partnership will advance the commercialization of small molecule oral STAT6 for patients around the world.

A 25-day BioLab study revealed their protein-rich wound gel outpaces alternatives, setting the stage for clinical trials.

Data augmentation techniques like cropping and blurring allow AI models to overcome limited datasets, improving skin cancer detection rates.

Researchers are advancing inclusive trials through ancestry-specific endpoints, focusing on skin tone variability, melanin's role, and precision drug modeling.

A study found that UK adults living with psoriasis and vitiligo were better able to self-manage the psychological implications of their condition.

In case you missed it, this week we had news about phase 2b enrollment for VYNE’s vitiligo gel, the impact of anti-inflammatory moisturizers for AD, the newly FDA-approved DermiSphere hDRT, and more.

Explore the top headlines of the week including clinical trial updates, FDA announcements, and expert insights.

At the inaugural Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, reviewed complex cases on AD and PsO and the role of PAs and NPs in advancing patient care.

93.4% of patients saw a positive change in the appearance of forehead wrinkles after 8 weeks of use.

Advancements in therapeutic agents demand innovative strategies for safe, localized skin treatments, Mitragotri argues.

Patients saw an average clearance rate of 74.46% after just 1 session of laser therapy.

Rezpegaldesleukin, a novel IL-2 receptor agonist, enters phase 2b evaluation for atopic dermatitis, aiming to advance therapeutic options for this chronic condition.

Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

The recommendations place an emphasis on the utility of ultrasound-guided placement to enhance safety.

A study revealed ruxolitinib cream's rapid, lasting benefits in pediatric eczema without systemic safety concerns over a 52-week trial period.

The 5% dosage showed a 6-fold increase in non-vellus hair count after just 5 weeks.

DFD-29, FDA-approved in 2024, revolutionizes rosacea management by addressing both erythema and inflammatory lesions with a novel extended-release formulation.

A recent systemic review found FRM to be an effective treatment modality on its own for managing facial acne scars.

Mitragotri said new innovations like ionic liquid-based delivery systems can offer better treatment for immunodermatological conditions.

UVF dermoscopy enhances scabies detection, especially in dark skin, with optimal results when combined with polarized light examination.

The company is currently recruiting participants to demonstrate the benefits of its BioREtain technology.

Designed to mimic natural tissue scaffolds, DermiSphere hDRT offers innovative support for cellular infiltration and healing in reconstructive surgery.

The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.

The synergistic approach reduced submental fullness, enhanced mandible line definition, and improved chin projection.